Meeting
2023 ASCO Annual Meeting
A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.
Authors
Stephen Joseph Bagley
Hospital of the University of Pennsylvania, Philadelphia, PA
Stephen Joseph Bagley , Suyash Mohan , Seyed Ali Nabavizadeh , Thara Patel , Timothy Prior , Maikel Mansour , Emily Mccoy , Natalie Angeloni , Meghan O'Neill , Karen Albright , Suzanne Frangos , Caroline Blessing , Leah Coghlan , Eileen Maloney , Arati Suvas Desai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03969706
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2045)
DOI
10.1200/JCO.2023.41.16_suppl.2045
Abstract #
2045
Poster Bd #
402
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.
First Author: Juan Manuel Sepulveda-Sanchez
Poster
2016 Genitourinary Cancers Symposium
Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study.
First Author: Vivek Narayan
Poster
2024 ASCO Annual Meeting
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.
First Author: Lei Liu
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu